In­smed’s PhII smokes and sput­ters, but re­searchers her­ald enough sur­pris­ing­ly pos­i­tive da­ta to roar on Wall Street

There was plen­ty not to like in In­smed’s Phase II read­out of an an­ti-in­flam­ma­to­ry drug dubbed INS1007.

The dose re­sponse didn’t pan out and in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.